Clinical Trial Update: MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia [NA]

View source ↗

Summary

Clinical trial update for MB-CART19.1 in relapsed/refractory acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: King Hussein Cancer Center | Conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent | NA | Status: RECRUITING